Body Composition and Exercise to Prevent Muscle Loss With GLP1 Agonist Treatment

NCT07226947 · Recruiting

Last updated 2026-05-28

This clinical trial is testing whether exercise can help prevent muscle loss in people with obesity who are taking a GLP-1 agonist medication.

Status Recruiting Currently enrolling participants.

Phase Not applicable Not a phased drug trial (e.g. a device or behavioral study).

Type Interventional (clinical trial)

Design Randomized, open-label (no blinding) treatment study

Participants 100 people Planned (estimated).

Who can join Ages 18–99 · all sexes

Timeline Started 2025-11 · est. completion 2027-06

Where 1 site · United States

What this study is testing ClinicalTrials.gov NCT07226947 ↗

Description as written by the study sponsor.

The goal of this study is to learn if a smartwatch that measures activity level and body composition, combined with exercise reminders, can safely improve strength and muscle mass in people who recently started or are planning to start treatment with incretin therapy (liraglutide, semaglutide, tirzepatide or retatrutide), also known as glucagon-like peptide 1 receptor agonist (GLP-1 RA) medications.

Treatments tested

Smartwatch activity and body composition monitor Device

Participants will be provided a smartwatch to monitor their exercise and body composition
General guidance on recommended exercise Behavioral

Participants will receive general guidance on recommended exercise

Main thing measured	Lean mass (kg)
Sponsor	Massachusetts General Hospital
Conditions studied	Obesity, Body Composition
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT07226947 ↗